Avicanna Inc.

AVCN

CA05368K1003

Biotechnology & Medical Research

Delayed Toronto S.E. Other stock markets 03:13:00 2024-04-16 pm EDT			5-day change	1st Jan Change
0.37 ^CAD	0.00%		-5.13%	+5.71%

Apr. 10	Avicanna Inc. Announces Completion of Topical Gel Observational Real-World Evidence Study	CI
Apr. 02	Transcript : Avicanna Inc., 2023 Earnings Call, Apr 02, 2024

This article is reserved for members

Already a member?

Not a member ?

Free registration

Latest news about Avicanna Inc.

Avicanna Inc. Announces Completion of Topical Gel Observational Real-World Evidence Study	Apr. 10	CI
Transcript : Avicanna Inc., 2023 Earnings Call, Apr 02, 2024	Apr. 02
Avicanna's Q4 Loss Narrows, Revenue Grows	Apr. 02	MT
Avicanna Brief: Reporting $16.8 Million in 2023 Revenue, representing an increase of 314% from 2022	Apr. 02	MT
Avicanna Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 01	CI
Avicanna Announced Canadian Launch of 10% CBD (THC Free) Proprietary Formulation	Mar. 27	MT
Avicanna Brief: Announcing Canadian Launch of 10% CBD (THC Free) Proprietary Formulation	Mar. 27	MT
Avicanna Inc Announces the Canadian Launch of 10% CBD (THC Free) Proprietary Formulation	Mar. 27	CI
ThreeD Capital Inc. Announces New YouTube Channel	Mar. 25	MT
Avicanna Reports New Research Collaboration With Multi-national European-based Pharmaceutical Firm; Down 5.6%	Feb. 15	MT
Avicanna Reports New Research Collaboration With Multi-national European-based Pharmaceutical Firm	Feb. 15	MT
Avicanna Brief: Announcing New Research Collaboration with a Multi-national European-based Pharmaceutical Company	Feb. 15	MT
Avicanna Inc. Announces New Research Collaboration with a Multi-National European-Based Pharmaceutical Company	Feb. 15	CI
Avicanna Brief: Adds Approval issued by the Health Authority of Colombia INVIMA for Adjuvant treatment for seizures associated with Lennox-Gastaut Syndrome (LGS) and Dravet Syndrome (DS)	Feb. 13	MT
Avicanna Brief: Says Obtained Its First Indication-Specific Drug Registration with Trunerox	Feb. 13	MT
Avicanna Inc. Obtains Its First Indication-Specific Drug Registration with Trunerox	Feb. 13	CI
Avicanna Signs Supply, Licensing Pact With Multinational Pharmaceutical Firm	Feb. 05	MT
Avicanna Inc. Announces Supply and Licensing Agreement with Multinational Pharmaceutical Company	Feb. 05	CI
Avicanna Brief: Also Involves Right of first refusal agreement for the Avicanna's SEDDs capsules in the European region	Feb. 05	MT
Avicanna Brief: Involves Exclusive supply agreement for two of Avicanna's proprietary topical products in the European region	Feb. 05	MT
Avicanna Brief: Announcing Supply and Licensing Agreement with Multinational Pharmaceutical Co	Feb. 05	MT
Avicanna and Ease Labs Pharma Granted Commercialization Approval for Pharmaceutical Preparation in Brazil	Jan. 30	MT
Avicanna Brief: Avicanna and Ease Labs Pharma Granted Commercialization Approval for Pharmaceutical Preparation in Brazil	Jan. 30	MT
Avicanna Inc. announced that it has received CAD 0.888128 million in funding	Dec. 03	CI
Transcript : Avicanna Inc., Q3 2023 Earnings Call, Nov 15, 2023	Nov. 15

Avicanna Inc. is a Canada-based commercial-stage international biopharmaceutical company. The Company's scientific platform commercializes over thirty products across various market segments: Medical Cannabis & Wellness Products (RHO Phyto), Pharmaceutical Pipeline and Medical Cannabis Care Platform (MyMedi.ca). RHO Phyto formulary offers a diverse range of proprietary formulations, including oral, sublingual, topical and transdermal delivery. It has developed a pipeline of patent-pending drug candidates that are indication specific and in various stages of clinical development and commercialization. These cannabinoid-based drug candidates look to address unmet medical needs in the areas of dermatology, chronic pain and various neurological disorders. Its first pharmaceutical preparation (Trunerox) is in the drug registration stage in South America. MyMedi.ca is a medical cannabis care platform that serves medical cannabis patientsâ needs and enhances the patient's journey.

Sector

Biotechnology & Medical Research

Calendar

2024-05-26 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
AVICANNA INC.	+5.71%	24.81M
LONZA GROUP AG	+48.77%	42.16B
IQVIA HOLDINGS INC.	-1.10%	42.07B
MODERNA, INC.	+4.72%	39.77B
CELLTRION, INC.	-11.36%	26.68B
ICON PUBLIC LIMITED COMPANY	+3.98%	24.68B
ALNYLAM PHARMACEUTICALS, INC.	-23.10%	18.68B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.87%	12.11B
MEDPACE HOLDINGS, INC.	+25.92%	11.99B
UNITED THERAPEUTICS CORPORATION	+4.89%	11.06B